Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended																			6 Months Ended		12 Months Ended
		Dec. 31, 2016		Oct. 01, 2016	[2]	Jul. 02, 2016	[3]	Apr. 02, 2016	[4]	Dec. 31, 2015		Sep. 26, 2015	[6]	Jun. 27, 2015	[7]	Mar. 28, 2015	[8]	Dec. 27, 2014	[9]	Sep. 27, 2014	Dec. 31, 2015	Dec. 27, 2014	Dec. 31, 2016	Jun. 27, 2015	Jun. 28, 2014	Oct. 22, 2015
Stock repurchase program, authorized amount										$ 3.3											$ 3.3
Stock repurchase program, remaining authorized repurchase amount		$ 1,500.0																					$ 1,500.0
Numerator:
Net income		$ (1,359.1)	[1]	$ (1,590.2)		$ (534.3)		$ (529.2)		$ (218.4)	[5]	$ 260.9		$ (22.2)		$ (22.2)		$ 151.1		$ 29.4	$ 42.5	$ 180.6	$ (4,012.8)	$ 136.1	$ 232.8
Denominator:
Weighted average shares outstanding for basic EPS (in shares)		143.4	[1]	143.3		143.2		143.2		144.9	[5]	146.3		146.3		140.8		136.3		133.9	145.6	135.1	143.3	139.3	115.1
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	[10]																				0.5		0.0	0.5	0.5
Weighted average shares outstanding for diluted EPS (in shares)		143.4	[1]	143.3		143.2		143.2		144.9	[5]	146.9		146.3		140.8		136.8		134.4	146.1	135.6	143.3	139.8	115.6
Antidilutive share-based awards oustanding	[10]																				0.1		0.0	0.1	0.1
Cash dividends																					$ (36.3)		$ (83.2)	$ (64.8)	$ (46.1)
Dividends declared per share (in dollars per share)																					$ 0.25	$ 0.21	$ 0.580	$ 0.4600	$ 0.3900
Accelerated Share Repurchases, Final Price Paid Per Share																					$ 151.59
Proceeds from (Repurchase of) Equity																					$ 500.0		$ 10.3	$ 35.7
Perrigo Co PLC [Member]
Stock repurchase program, authorized amount																										$ 2,000.0

[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9

[2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million.

[3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million.

[4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million.

[5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.

[6] Includes Mylan defense-related fees of $15.6 million.

[7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.

[8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.

[9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million.

[10] In the period of a net loss, diluted shares equal basic shares.